Page 178 - Eceptor News Today

Researchers studied the complex structure of the receptor-binding domain of the omicron variant with the human host receptor angiotensin-converting enzyme 2.

Researchers generated a set of computed structural models of the Omicron receptor-binding domain attached to its receptor angiotensin-converting enzyme.

Researchers compared the binding of the new SARS-CoV-2 VOC Omicron’s RBD and ACE2 receptor with the original Wuhan SARS-CoV-2 strain and other VOCs such as Beta and Delta.

Scientists from Germany have recently pointed out that the third booster dose of mRNA-based COVID-19 vaccine is highly effective in neutralizing the omicron variant of SARS-CoV-2.

The final results from a national phase 2 study including researchers from Yale Cancer Center show the drug tipifarnib increased survival rates for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

Scientists have recently reported the efficacy of carrageenan against both the SARS-CoV-2 original strain as well as the Alpha, Beta, Gamma, and Delta VOCs.

Largely, scientists are skeptical that the Omicron variant can infect vaccinated individuals. However, a new study published on the medRxiv* preprint server has conducted neutralization assays using an Omicron isolate obtained from patients residing in the United Kingdom.

A new study published on the bioRxiv preprint server has hypothesized that T cell receptors (TCR) repertoire can measure the response to vaccines, as it would identify the TCR of clones that respond to the vaccination.

Largely, scientists are skeptical that the Omicron variant can infect vaccinated individuals. However, a new study published on the medRxiv* preprint server has conducted neutralization assays using an Omicron isolate obtained from patients residing in the United Kingdom.

Chimeric antigen receptor T-cell therapy or CAR T is a breakthrough treatment for patients with certain types of blood cancers.